Aurobindo Pharma shares in focus after Eugia Steriles unit gets USFDA observations

Shares of Aurobindo Pharma Ltd. will be in focus on Monday, June 22, after the company disclosed the outcome of a recent inspection by the US Food and Drug Administration (US FDA) at its Eugia Steriles facility.

The US FDA conducted a Pre-Approval Inspection (PAI) at Eugia Steriles, a wholly-owned subsidiary of Eugia Pharma Specialities Ltd. and a step-down subsidiary of Aurobindo Pharma, located in Parawada Mandal, Anakapalli district of Andhra Pradesh.

The inspection was carried out between June 10 and June 19, 2026.

At the conclusion of the inspection, the regulator issued a Form 483 with five observations. The company said it will submit its response to the observations within the stipulated timeline.

Aurobindo Pharma clarified that the inspection outcome has no impact on the company's operations or financial performance.

Last week, Aurobindo Pharma announced plans to divest four generic pharmaceutical products as part of the regulatory process to complete its proposed $250 million acquisition of US-based Lannett Company.

Aurobindo said the products will be divested to Quagen Pharmaceuticals to address regulatory requirements linked to the transaction.

The acquisition is expected to strengthen Aurobindo's presence in the US generics market and provide opportunities for operational synergies and margin expansion.

Shares of Aurobindo Pharma ended Monday's session 3.87% higher at ₹1,499.50. The stock has gained nearly 26% so far in 2026.